echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > EBioMedicine: Disnews! University of Southern California study: Omega-3 fatty acids in fish don't prevent Alzheimer's disease!

    EBioMedicine: Disnews! University of Southern California study: Omega-3 fatty acids in fish don't prevent Alzheimer's disease!

    • Last Update: 2020-07-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Introduction: Earlier studies have shown that fish content and these two omega fatty acids are beneficial to brain function in older adults and may reduce the risk of Alzheimer's disease in older people

    A new study recently contradicted this

    A small trial at the University of Southern California found that omega fatty acids in fish have less effect on the brain and do not prevent Alzheimer's disease

    For years, a scientific conundrum has plagued researchers working to fight Alzheimer's disease, which is incurable

    Alzheimer's disease is a neurodegenerative brain disease in the brain that destroys brain cells that cause abnormal memory, cognition, thinking and behavioral abilities to seriously affect people's work and life until the body loses function

    It is the most common type of dementia

    Previous epidemiological studies and meta-studies of famous participants showed that omega fatty acids have the potential to prevent Alzheimer's disease, "good fats" are found in fish

    So far, however, most studies that have assessed human cognitive decline have not shown any benefit

    Now a small clinical trial at the University of Southern California has provided important clues to this phenomenon

    This is the first time that researchers who have revealed whether omega siscant disease can prevent Alzheimer's disease have compared omegas in the blood to levels in the central nervous system

    The results suggest that more doses of omega fatty acid supplements may be required to change this situation because of a sharp rise in omega fatty acid levels in the blood and a particularly slow increase in omega fatty acid levels in the brain

    For participants who carried a specific mutation that increased their risk of developing Alzheimer's disease, the level of a key fatty acid raised by taking supplements was much lower than in those who did not

    "The experiment was based on the assumption that the omega will enter the brain," said Dr

    Hussain Yassin, an associate professor of medicine and neurology at the University of Southern California's Keck School of Medicine and senior author of the study

    Our research is specifically designed to solve this problem

    The paper was published in the journal Biomedical

    The researchers recruited participants with risk factors for Alzheimer's disease but no cognitive impairment

    All participants had a family history of the disease, a sedentary lifestyle and a low-fat fish diet

    One person carries a gene called a gene variant that is associated with inflammation in the brain that increases the risk of Alzheimer's disease by four or more; Participants in the demographics and baseline clinical characteristics of the treatment group were randomly assigned to the treatment group and the control group

    Members of the treatment group were required to take more than grams of omega-22 hexaxaric acid () supplements daily for several months

    The control group members were given a placebo daily during the same period

    Both groups of participants were also asked to take daily multivitamins that helped the body process omega-fatty acids

    Dr Yassin and his colleagues collected plasma and cerebrospinal fluid samples from participants at the beginning of the study and at the end of the study to measure whether omega fatty acids reach edited in the brain

    The scientists observed that the levels of two omega-fatty acids, a very effective anti-inflammatory substance, can be produced by a small amount of an effective anti-inflammatory substance

    Is high doses of omega fatty acids effective? The researchers found that participants who took omega supplements after six months had higher levels of blood than those who took a placebo

    In contrast, the content of cerebrospinal fluid in the treatment group was only higher than in the control group

    The results suggest that measuring the amount of omega in the blood does not indicate how much reaches the brain

    In the treatment group, people who were not at risk of mutation had three times more levels in cerebrospinal fluid (anti-inflammatory omega fatty acids) than those carrying the gene

    It is worth noting that the dose of grams in this study far exceeds that of the dose stake that tested in large clinical trials to prevent Alzheimer's disease, which is usually taken daily or less

    It may not be considered pointless to use a low-dose brain to increase the amount of omega

    The sacrifice of the study participants led to the study of Alzheimer's disease, which researchers spent two years recruiting participants

    The obstacle to the study comes from the only way to extract cerebrospinal fluid: lumbar punctures are also known as spinal punctures

    Finding someone willing to undergo the procedure has proved challenging, requiring a hollow needle to pierce the waist twice

    Dr Yassin spoke highly of the study participants

    He believes that the participants in the study contributed to the development of science

    Over a two-year period, the study will study participants to determine whether high doses of omega fatty acids can slow cognitive decline in lipoprotein gene carriers

    "These preliminary studies are a very important step towards larger, more complex studies," said Dr Yassin, who has changed cognitive scoring

    Progress from small studies to large-scale studies is a good model for developing brain-specific therapies and prevention

    The bottom line is that before you start a very expensive clinical trial, you need to prove that your drug is entering the brain and changing the biomarkers of the disease in the right direction

    "
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.